Endometrial Clinical Trials

323 recruitingLast updated: May 29, 2026

There are 323 actively recruiting endometrial clinical trials across 51 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Early Phase 1, Phase 4. Top locations include Houston, Texas, United States, New York, New York, United States, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


Endometrial Trials at a Glance

323 actively recruiting trials for endometrial are listed on ClinicalTrialsFinder across 6 cities in 51 countries. The largest study group is Phase 2 with 103 trials, with the heaviest enrollment activity in Houston, New York, and Boston. Lead sponsors running endometrial studies include AstraZeneca, Mayo Clinic, and National Cancer Institute (NCI).

Browse endometrial trials by phase

Treatments under study

About Endometrial Clinical Trials

Looking for clinical trials for Endometrial? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Endometrial trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Endometrial clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 323 trials

Recruiting
Phase 3

Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer

Endometrial Cancer
Daiichi Sankyo710 enrolled61 locationsNCT07022483
Recruiting
Phase 3

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

Advanced Endometrial CarcinomaRecurrent Endometrial Carcinoma
National Cancer Institute (NCI)255 enrolled192 locationsNCT07198074
Recruiting
Phase 1

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

Endometrial CancerColorectal CarcinomaNon-small Cell Lung Cancer+3 more
AstraZeneca108 enrolled18 locationsNCT06218914
Recruiting
Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more
National Cancer Institute (NCI)2,900 enrolled479 locationsNCT05564377
Recruiting
Phase 3

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Endometrial CarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Dedifferentiated Carcinoma+5 more
National Cancer Institute (NCI)360 enrolled408 locationsNCT05256225
Recruiting
Phase 3

Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months

Endometrial Hyperplasia
Bayer207 enrolled87 locationsNCT06904274
Recruiting
Phase 1

A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)

Advanced Relapsed or Refractory Germ Cell TumoursAdvanced Relapsed or Refractory Endometrial CancerAdvanced Relapsed or Refractory Ovarian Cancer
Boehringer Ingelheim187 enrolled13 locationsNCT07306559
Recruiting
Phase 1Phase 2

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Colorectal, CancerProstate CancerCancer+12 more
Parabilis Medicines, Inc.595 enrolled33 locationsNCT05919264
Recruiting
Phase 2

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

Recurrent Ovarian CarcinomaRecurrent Endometrial CarcinomaRecurrent Fallopian Tube Carcinoma+1 more
National Cancer Institute (NCI)165 enrolled296 locationsNCT05554328
Recruiting
Phase 1Phase 2

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Triple-Negative Breast CancerEndometrial CancerPrimary Peritoneal Carcinoma+12 more
Genmab884 enrolled66 locationsNCT05579366
Recruiting
Phase 2

Ph 2 Elacestrant in ER Positive Uterine Sarcomas

Estrogen Receptor Positive TumorEndometrial Stromal SarcomaUterine Sarcoma+6 more
Dana-Farber Cancer Institute30 enrolled1 locationNCT07467772
Recruiting
Phase 3

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

Endometrial Cancer
Merck Sharp & Dohme LLC1,123 enrolled250 locationsNCT06952504
Recruiting
Phase 1

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

Breast NeoplasmsColorectal NeoplasmsProstate Neoplasm+2 more
Eli Lilly and Company421 enrolled29 locationsNCT07114601
Recruiting
Phase 1Phase 2

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

Breast CancerOvarian CancerCervical Cancer+5 more
Terremoto Biosciences Inc.205 enrolled15 locationsNCT07109726
Recruiting
Phase 2

A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer

Endometrial Cancer
Memorial Sloan Kettering Cancer Center75 enrolled7 locationsNCT07209449
Recruiting
Phase 1

A Phase I Interventional Open-label, Non-randomized Dose-escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients With Selected Advanced Cancers.

Metastatic Breast CancerMetastatic Gastric CancerEndometrial Cancer Metastatic
Vall d'Hebron Institute of Oncology15 enrolled2 locationsNCT07593820
Recruiting
Phase 3

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

Endometrial Cancer
BioNTech SE480 enrolled156 locationsNCT06340568
Recruiting
Phase 3

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

Endometrial CancerMalignant Solid Tumour
AstraZeneca700 enrolled314 locationsNCT07044336
Recruiting
Phase 1

Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer

Endometrial Cancer
M.D. Anderson Cancer Center21 enrolled1 locationNCT05819892
Recruiting

Preoperative Risk Stratification in Endometrial Cancer for Tailoring Lymph Node Staging

Endometrial Cancer
University Hospital Hradec Kralove350 enrolled1 locationNCT07368205